2.44
In 8 Bio Inc stock is traded at $2.44, with a volume of 119.86K.
It is up +1.24% in the last 24 hours and up +11.93% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.41
Open:
$2.42
24h Volume:
119.86K
Relative Volume:
0.65
Market Cap:
$7.38M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-3.2533
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+12.44%
1M Performance:
+11.93%
6M Performance:
-70.42%
1Y Performance:
-89.99%
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
INAB
In 8 Bio Inc
|
2.44 | 8.30M | 0 | -31.88M | -25.20M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-18-24 | Initiated | Laidlaw | Buy |
Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Will Passage Bio Inc. stock benefit from interest rate changesAccelerated earnings growth - jammulinksnews.com
Layoff Tracker: Flagship Unicorns Tessera, Generate:Biomedicines Downsize - BioSpace
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - Stock Titan
Tourmaline Bio Inc. Stock Analysis and ForecastHigh-yield market plays - jammulinksnews.com
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
What analysts say about 2seventy bio Inc. stockExceptional return forecasts - Autocar Professional
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
What drives Mustang Bio Inc. stock priceMarket-leading growth rates - jammulinksnews.com
What analysts say about TELA Bio Inc. stockBreakout stock performance - Jammu Links News
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What drives Boundless Bio Inc. stock pricePowerful profit generation - jammulinksnews.com
Gossamer Bio Inc. Stock Analysis and ForecastMarket-leading capital gains - jammulinksnews.com
Why Climb Bio Inc. stock attracts strong analyst attentionEntry Level Low Risk Picks - Newser
Why Kronos Bio Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors - GlobeNewswire
Pre-market Movers: CLDI, BMGL, PROK, RXST... - RTTNews
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer - Yahoo Finance
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - Yahoo Finance
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire
Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan
Breakthrough: New Alzheimer's Drug XPro Shows Promise in Key Patient Group, Zero ARIA Cases - Stock Titan
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Clinical-Stage Immunology Company INmune Bio Secures $19M from Healthcare Investors at Market Price - Stock Titan
Major Alzheimer's Treatment Milestone: INmune Bio Reveals Phase 2 Trial Results Next Week - Stock Titan
BioCryst's ORLADEYO Pediatric HAE Review Extended by FDA to December 2025 | BCRX SEC FilingForm 8-K - Stock Titan
Breakthrough in Dementia Treatment: Gene Therapy Maintains 18-Month Efficacy with Lower Dose Success - Stock Titan
ANVS gains NYSE approval of compliance plan, delisting risk eased | ANVS SEC FilingForm 8-K - Stock Titan
Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight - GlobeNewswire
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Quantisnow
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - Yahoo Finance
Breakthrough: New Drug Reduces Alzheimer's Risk After Brain Injury, DoD-Backed Study Shows - Stock Titan
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewswire Inc.
European Launch: TELA Bio's Natural Hernia Repair Device Shows 98.8% Success Rate - Stock Titan
TELA Bio Appoints Jeffrey Blizard as President - GlobeNewswire
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis - GlobeNewswire
Global Immunoprecipitation Market Set to Grow at a CAGR of 6-8%: Key Drivers and Challenges by 2029 - PharmiWeb.com
DNA Polymerase Market to Grow at 6–8% CAGR Driven by Genomics, PCR, and CRISPR Technologies by 2029 - PharmiWeb.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
Caisse Française de Financement Local: EMTN 2025-8 SOCIAL - The Manila Times
Protagenic Therapeutics Completes Acquisition of Phytanix Bio - TipRanks
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan
KALA BIO: Q1 Earnings Snapshot - The Washington Post
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):